Patents by Inventor Robert J. Hariri

Robert J. Hariri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10835576
    Abstract: Embodiments of the present invention are generally related to methods of obtaining effective amount of avian follistatin. More specifically, embodiments of the present invention relate to products comprising avian follistatin, and methods of optimizing the same based on avian follistatin concentrations utilized during the manufacturing process. In one embodiment of the present invention, a method of creating a consumable product for treatment of a muscle degenerating disease having avian follistatin comprises selecting an avian egg based upon a desired threshold of avian follistatin concentration therein; extracting material from the avian egg, the material comprising avian follistatin; and processing the material with one or more excipients to yield the consumable product.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: November 17, 2020
    Assignee: MYOS RENS TECHNOLOGY INC.
    Inventors: Neerav Padliya, Robert J. Hariri, Carlon Colker
  • Publication number: 20200246393
    Abstract: Provided herein are methods of suppressing the growth or proliferation of tumor cells and methods of treating individuals having tumor cells using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer (PINK) cells, combined natural killer (NK) cells, or combinations thereof, in combination with an antibody (e.g., anti-disialoganglioside (anti-GD2) antibody). Also provided herein are compositions comprising placental perfusate, placental perfusate cells, PINK cells, combined NK cells, or combinations thereof, in combination with an antibody (e.g., anti-GD2 antibody).
    Type: Application
    Filed: September 27, 2018
    Publication date: August 6, 2020
    Applicant: CELULARITY, INC.
    Inventors: Xiaokui ZHANG, Lin KANG, Robert J. HARIRI
  • Publication number: 20200246385
    Abstract: Provided herein are micro-organoids, referred to herein as Functional Physiological Units (FPUs), that are capable of replacing or augmenting one or more physiological functions in an individual, which are useful in the treatment of individuals lacking, or suffering a deficit in, said physiological function.
    Type: Application
    Filed: April 21, 2020
    Publication date: August 6, 2020
    Applicant: Celularity Inc.
    Inventors: Robert J. HARIRI, Mohit BHATIA, Jia-Lun WANG, Wolfgang HOFGARTNER, Qian YE
  • Publication number: 20200188446
    Abstract: A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.
    Type: Application
    Filed: February 24, 2020
    Publication date: June 18, 2020
    Applicant: CELULARITY, INC.
    Inventor: Robert J. Hariri
  • Publication number: 20200048603
    Abstract: Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to combinations of nanofibrous scaffolds and adherent placental stem cells and methods of using the same in cartilage repair. Finally, provided herein are compositions and methods relating to nonadherent, CD34+CD45? stem cells from placenta.
    Type: Application
    Filed: October 18, 2019
    Publication date: February 13, 2020
    Applicant: CELULARITY, INC.
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Marian Pereira, Sascha Dawn Abramson, Kristen S. Labazzo
  • Publication number: 20200009199
    Abstract: The present invention provides cytotherapeutic units comprising predetermined numbers of selected types of potent cells. Assurance of the nature and identities of such cells is achieved through assay and certification of said numbers and identities. Therapeutic modalities are provided. Libraries of cell preparations with assayed and preferably certified populations are preferred and the preparation of cell preparations tailored to specific patients or disease states are provided.
    Type: Application
    Filed: August 5, 2019
    Publication date: January 9, 2020
    Applicant: CELULARITY, INC.
    Inventor: Robert J. Hariri
  • Patent number: 10494607
    Abstract: Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to combinations of nanofibrous scaffolds and adherent placental stem cells and methods of using the same in cartilage repair. Finally, provided herein are compositions and methods relating to nonadherent, CD34+CD45? stem cells from placenta.
    Type: Grant
    Filed: February 12, 2008
    Date of Patent: December 3, 2019
    Assignee: CELULARITY, INC.
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Marian Pereira, Sascha Dawn Abramson, Kristen S. Labazzo
  • Publication number: 20190330592
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: July 3, 2019
    Publication date: October 31, 2019
    Applicant: Celularity, Inc.
    Inventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
  • Publication number: 20190321413
    Abstract: The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood stem cells, particularly autologous cord blood cells, and placental stem cells for the treatment of premature infants.
    Type: Application
    Filed: May 30, 2019
    Publication date: October 24, 2019
    Applicant: CELULARITY, INC.
    Inventors: Mohammad A. Heidaran, Robert J. Hariri, Kristine Erickson Johnson
  • Publication number: 20190314424
    Abstract: Provided herein are methods of using tissue culture plastic-adherent placental adherent cells, e.g. placental stem cells, referred to herein as placental adherent cells, to treat lymphedema and lymphedema-related disorders.
    Type: Application
    Filed: December 6, 2017
    Publication date: October 17, 2019
    Applicant: CELULARITY, INC.
    Inventors: Robert J. Hariri, Shuyang He
  • Publication number: 20190262406
    Abstract: Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.
    Type: Application
    Filed: September 21, 2018
    Publication date: August 29, 2019
    Applicant: CELULARITY, INC.
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Kristen S. Labazzo, Marian Pereira, Sascha Dawn Abramson
  • Publication number: 20190117705
    Abstract: Provided herein are compositions comprising mononuclear cells from human placental perfusate and methods of using such cells, including using the cells together with hematopoietic cells, for example to establish chimerism, reduce the severity or duration of graft versus host disease, treat or ameliorate symptoms of sarcopenia, metabolic disorders and hematologic disorders, such as hematologic malignancies, and treat or ameliorate symptoms of ischemic encephalopathy (e.g., hypoxic ischemic encephalopathy) and other central nervous system injuries.
    Type: Application
    Filed: November 23, 2018
    Publication date: April 25, 2019
    Applicant: CELULARITY, INC.
    Inventors: Jodi P. Gurney, Xiaokui Zhang, Stacy Herb, Robert J. Hariri
  • Publication number: 20190093081
    Abstract: Provided provided herein are methods of treating a subject having a brain tumor, e.g., a glioblastoma by administering to the subject an effective amount of a cell population comprising human placenta-derived natural killer cells. Also provided are methods of suppressing the growth of brain tumor cells comprising contacting the glioblastoma cells with an effective amount of a cell population comprising human placenta-derived natural killer cells. Further provided are compositions comprising subject an effective amount of a cell population comprising human placenta-derived natural killer cells for use in the treatment of a brain tumor in a subject or for use in the manufacture of a medicament for treatment of a brain tumor in a subject.
    Type: Application
    Filed: September 28, 2018
    Publication date: March 28, 2019
    Applicant: CELULARITY, INC.
    Inventors: Lin KANG, Xiaokui ZHANG, William VAN DER TOUW, Robert J. HARIRI, Shuyang HE
  • Patent number: 10179152
    Abstract: Provided herein are methods of treatment comprising administering to a subject, e.g., a human subject, mononuclear cells from human placental perfusate and hematopoietic cells, and compositions comprising them, and their uses to establish chimerism, engraft tissue (e.g., blood), reduce the severity or duration of graft versus host disease, and treat or ameliorate symptoms of metabolic disorders and hematologic disorders, such as hematologic malignancies.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: January 15, 2019
    Assignee: Celularity, Inc.
    Inventors: Jodi P. Gurney, Xiaokui Zhang, Stacy Herb, Robert J. Hariri
  • Publication number: 20180346877
    Abstract: Provided herein are methods of producing natural killer (NK) cells and/or ILC3 cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.
    Type: Application
    Filed: October 14, 2016
    Publication date: December 6, 2018
    Applicant: CELULARITY, INC.
    Inventors: Xiaokui ZHANG, Ivana DJURETIC, Lin KANG, Vanessa VOSKINARIAN-BERSE, Bhavani STOUT, Robert J. HARIRI, Wolfgang HOFGARTNER, James EDINGER, Eric LAW, Vladimir JANKOVIC
  • Patent number: 10113146
    Abstract: A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: October 30, 2018
    Assignee: CELULARITY, INC.
    Inventor: Robert J. Hariri
  • Patent number: 10105399
    Abstract: Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: October 23, 2018
    Assignee: CELULARITY, INC.
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Kristen S. Labazzo, Marian Pereira, Sascha Dawn Abramson
  • Publication number: 20180298328
    Abstract: Provided herein are stimulated placental stem cells and methods of treating individuals having diseases or disorders of the circulatory system using stimulated placental cells. The invention also provides methods of inducing angiogenesis using such stimulated cells or populations of cells comprising such stimulated cells.
    Type: Application
    Filed: May 25, 2016
    Publication date: October 18, 2018
    Applicant: Celularity, Inc.
    Inventors: Kathy E. KARASIEWICZ-MENDEZ, Aleksandar FRANCKI, Jeffrey TURNER, Eric LAW, Jennifer PAREDES, Kristen LABAZZO, Hemlata RANA, Wolfgang HOFGARTNER, Robert J. HARIRI
  • Patent number: 9925221
    Abstract: Provided herein are methods of treatment of an individual having amyotrophic lateral sclerosis, comprising administering to the individual a therapeutically effective amount of placental stem cells, e.g., tissue culture surface-adherent placental stem cells (PDACs). In one aspect, provided herein is a method of treating amyotrophic lateral sclerosis (ALS) comprising administering to an individual having ALS a therapeutically effective amount of placental stem cells. In certain embodiments, “therapeutically effective” means an amount effective to reduce or ameliorate one or more symptoms of ALS.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: March 27, 2018
    Assignee: Celularity, Inc.
    Inventors: Robert J. Hariri, Jodi P. Gurney
  • Publication number: 20180071343
    Abstract: Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells.
    Type: Application
    Filed: November 16, 2017
    Publication date: March 15, 2018
    Applicant: Celularity, Inc.
    Inventors: Stewart Abbot, James Edinger, Aleksander Francki, Robert J. Hariri, Vladimir Jankovic, Aleksandr Kaplunovsky, Kristen Labazzo, Eric Law, Neerav Padliya, Jennifer Paredes, Jia-Lun Wang